This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic.
Pfizer and BioNTech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals.
The distribution of the vaccine in the UK will be prioritized according to the populations identified in guidance from the Joint Committee on Vaccination and Immunisation.
The MHRA's decision is based on a rolling submission, including data from the Phase 3 clinical study, which demonstrated a vaccine efficacy rate of 95% (p
Grifols to start Spanish clinical trial for new COVID-19 drug
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Grifols Starts Clinical Trial of New Treatment to Provide Immediate Immunity Against COVID-19
Dr. Reddy's Laboratories to begin phase 3 study of Sputnik V vaccine in India
Sirnaomics completes dose administration for first patient in Phase 2a STP705 clinical study